Preferred Name | Tofacitinib | |
Synonyms |
|
|
Definitions |
An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C95800 |
|
CAS_Registry |
477600-75-2 |
|
Chemical_Formula |
C16H20N6O |
|
code |
C95800 |
|
Contributing_Source |
FDA |
|
definition |
An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. |
|
FDA_UNII_Code |
87LA6FU830 |
|
Has_Salt_Form | ||
in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 |
|
label |
Tofacitinib |
|
NCI_Drug_Dictionary_ID |
759505 |
|
PDQ_Closed_Trial_Search_ID |
759505 |
|
PDQ_Open_Trial_Search_ID |
759505 |
|
Preferred_Name |
Tofacitinib |
|
prefixIRI |
NCIT:C95800 |
|
prefLabel |
Tofacitinib |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C2930696 |
|
subClassOf |